Chan Yoon

Chan Yoon

Auto-generated profile, based on publicly available information

Chan Yoon

EverEx, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
TKTae Gyun Kim
Tae Gyun Kim
SMSang Young Moon
Sang Young Moon
MPMoon Seok Park
Moon Seok Park
SKSoon-Sun Kwon
Soon-Sun Kwon
KJKi Jin Jung
Ki Jin Jung
KLKyoung Min Lee
Kyoung Min Lee
Kim TG, et al. J Korean Med Sci. 2016 Jan;31(1):120-124. http://dx.doi.org/10.3346/jkms.2016.31.1.120

27 October 2021 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
MCMoon Jong Chang
Moon Jong Chang
JSJoung Youp Shin
Joung Youp Shin
CYChan Yoon
Chan Yoon
TKTae-Woo Kim
Tae-Woo Kim
CCChong Bum Chang
Chong Bum Chang
SKSeung-Baik Kang
Seung-Baik Kang
Background: Tranexamic acid (TXA) is typically discontinued on the day of total knee arthroplasty (TKA). However, bleeding may persist for several days. We sought to determine whether sequential administration of intravenous (IV) and oral TXA could reduce hemoglobin (Hb) drop more than IV TXA alone. We also wanted to determine whether the use of additional oral TXA increased the rate of complications of deep vein thrombosis (DVT) or symptomatic pulmonary embolism (PE). Methods: This prospective, randomized controlled trial included 141 patients. We compared the Hb drop, estimated blood loss (EBL), and transfusion rate of patients receiving IV TXA alone (group IV, n = 48) to those of patients who received IV TXA followed by oral TXA for 2 days (group 2D, n = 46) or 5 days (group 5D, n = 47). IV TXA was administered 10 minutes prior to the tourniquet release and 3 hours after the first IV TXA administration. Computed tomography (CT) was performed on postoperative day 6 to identify radiographic evidence of DVT. We also assessed the prevalence of symptomatic DVT and PE. Results: There were no differences in maximal Hb drop, Hb drops measured at each time point, EBL, or transfusion rate among the 3 groups. The mean maximal Hb drop was 3.5 g/dL in group IV, 3.2 g/dL in group 2D, and 3.4 g/dL in group 5D. The mean EBL was 999.9 mL in group IV, 886.4 mL in group 2D, and 972.5 mL in group 5D. One patient in each group required a transfusion. There were no differences in the prevalence of radiographic evidence of DVT or symptomatic DVT. Symptomatic DVT occurred in 3 patients in group IV and 2 patients in group 5D. One patient in group IV developed a symptomatic PE. Conclusions: Although there was no increase in the complication rate, the sequential administration of oral TXA for up to 5 days after IV TXA did not decrease Hb drop. Therefore, our findings suggest that sequential use of oral and IV TXA is not recommended. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

17 October 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
SLSanghee Lee
Sanghee Lee
CYChan Yoon
Chan Yoon
CCChi-Hyun Choi
Chi-Hyun Choi
TPTae Hyun Park
Tae Hyun Park
SYSang-Jin Yang
Sang-Jin Yang
CCChong Bum Chang
Chong Bum Chang
Background: Patellofemoral pain (PFP) is a common musculoskeletal disorder characterized by persistent knee pain, often without any structural abnormalities. Conservative treatments, particularly exercise therapy, are widely recommended; however, adherence remains generally low, and full recovery is often not achieved. Psychological interventions can aid in symptom management; however, studies integrating cognitive behavioral therapy (CBT), which is known to be effective for chronic pain, with exercise therapy for patients with PFP are limited. This study examined the impact of MORA Cure (PFP), a multidisciplinary digital therapeutics (DTx) app that integrates exercise and CBT, in comparison with conventional treatments for PFP management. Objective: This study aimed to evaluate the efficacy and safety of an 8-week DTx intervention incorporating exercise and CBT compared with in-person exercise education in patients with PFP. Methods: A parallel-group randomized controlled trial was conducted with 35 patients diagnosed with PFP recruited from orthopedic outpatient clinics. Participants were randomly assigned to either the DTx group (n=18, 51%) or the control group (n=17, 49%). The DTx group received an 8-week intervention via the MORA Cure (PFP) app incorporating home-based exercises and weekly CBT modules with daily worksheets. The control group received conventional treatment, including disease education, a single in-person exercise education session conducted by a medical professional, and encouragement to continue self-exercising throughout the study period. The outcome measures included pain severity (usual and worst, assessed using the numeric pain rating scale), functional disability (Anterior Knee Pain Scale), knee extension strength (measured using an isokinetic dynamometer), health-related quality of life (EQ-5D), and mental health status (9-item Patient Health Questionnaire). Assessments were conducted from baseline at 4-week intervals for up to 12 weeks. Results: The DTx group showed significant reductions in usual pain at each time point (4 weeks: mean score 2.2, SD 1.5, and P=.006; 8 weeks: mean 2.3, SD 1.7, and P=.003; 12 weeks: mean 1.2, SD 1.8, and P=.008), whereas the control group exhibited no changes. The knee extension strength in the DTx group increased significantly at both 8 and 12 weeks (P<.001), with greater improvement than that in the control group at 8 weeks (P=.04). Both groups showed significant improvements in functional disability at 12 weeks (DTx: mean score 85.2, SD 12.7, and P=.006; control: mean 84.5, SD 13.0, and P=.01). Health-related quality of life (EQ-5D) also improved in the DTx group at 8 and 12 weeks, whereas the control group showed improvement only at 12 weeks. Conclusions: This multidisciplinary DTx intervention was associated with significant pain reduction, improved functional disability, and increased knee extension strength in patients with PFP. These findings underscore the promise of DTx in PFP management and their potential to enhance patient outcomes. Trial Registration: ClinicalTrials.gov NCT05614583; https://clinicaltrials.gov/study/NCT05614583

1 January 2025 in Journal of Korean Society of Spine Surgery
Verified
Journal Article
Open access
PDF file
SLSanghee Lee
Sanghee Lee
CYChan Yoon
Chan Yoon
SPSung Cheol Park
Sung Cheol Park
YYYongjin You
Yongjin You
이상희, et al. J Korean Soc Spine Surg. 2025 Jun;32(2):31-36. https://doi.org/10.4184/jkss.2025.32.2.31

10 December 2024 in JMIR Preprints
Verified
Preprint
Open access
SLSanghee Lee
Sanghee Lee
CYChan Yoon
Chan Yoon
CCChi-Hyun Choi
Chi-Hyun Choi
TPTae Hyun Park
Tae Hyun Park
SYSang-Jin Yang
Sang-Jin Yang
CCChong Bum Chang
Chong Bum Chang
BACKGROUND Patellofemoral pain (PFP) is a common musculoskeletal disorder characterized by persistent knee pain, often without any structural abnormalities. Conservative treatments, particularly exercise therapy, are widely recommended; however, adherence remains generally low and full recovery is often not achieved. Psychological interventions can aid in symptom management; however, studies integrating cognitive behavioral therapy (CBT), which is known to be effective for chronic pain, with exercise therapy for patients with PFP are limited. This study examined the impact of MORA Cure (PFP), a multidisciplinary digital therapeutic device that integrates exercise and CBT, in comparison with conventional treatments for PFP management. OBJECTIVE This study aimed to evaluate the efficacy and safety of an 8-week digital therapeutic intervention incorporating exercise and CBT compared with in-person exercise education in patients with PFP. METHODS A parallel-group randomized controlled trial was conducted with 35 patients diagnosed with PFP, recruited from orthopedic outpatient clinics. Participants were randomly assigned to either the digital therapeutics (DT) group (n = 18) or the control group (n = 17). The DT group received an 8-week intervention via the MORA Cure (PFP) application, incorporating home-based exercises and weekly CBT modules. The control group received conventional treatment including disease education, a single in-person exercise education session conducted by a medical professional, and encouragement to continue self-exercising throughout the study period. The outcome measures included pain severity (usual and worst, assessed using the Numeric Pain Rating Scale), functional disability (Anterior Knee Pain Scale), knee extension strength (measured with an isokinetic dynamometer), health-related quality of life (EQ-5D), and mental health status (Patient Health Questionnaire-9). Assessments were conducted from baseline at 4-week intervals for up to 12 weeks. RESULTS The DT group showed significant reductions in usual pain at each time point: 4 (2.2 ± 1.5, p = 0.006), 8 (2.3 ± 1.7, p = 0.003), and 12 (1.2 ± 1.8, p = 0.008) weeks, whereas the control group demonstrated no changes. However, between-group differences in pain reduction were not statistically significant. The knee extension strength in the DT group increased significantly at both 8 and 12 weeks (p < 0.001), with greater improvement than that in the control group at 8 weeks (p = 0.039). Both groups showed significant improvements in functional disability at 12 weeks (DT: 85.2 ± 12.7, p = 0.006; Control: 84.5 ± 13.0, p = 0.010). Health-related quality of life (EQ-5D) also improved in the DT group at 8 and 12 weeks, whereas the control group showed improvement only at 12 weeks. CONCLUSIONS This multidisciplinary digital therapeutic intervention was associated with significant pain reduction, improved functional disability, and increased knee extension strength in patients with PFP. These findings underscore the promise of digital therapeutics in PFP management and their potential to enhance patient outcomes. CLINICALTRIAL ClinicalTrials.gov (NCT05614583).